###begin article-title 0
###xml 49 54 49 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 64 73 64 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 78 81 78 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 89 93 89 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1</italic>
###xml 452 457 452 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 477 486 477 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 536 541 536 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 573 578 573 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 117 122 <span type="species:ncbi:9606">human</span>
A 40-bp variable number of tandem repeats (VNTR) polymorphism exists in the 15th exon of DAT1, the gene encoding the human dopamine transporter (DAT). Though the VNTR resides in a region encoding the 3' untranslated region (UTR) and does not alter the protein's amino acid sequence, the prevalent 10-repeat variant has shown both linkage and association to Attention Deficit Hyperactivity Disorder (ADHD). In this study, we examined the effects of the DAT1 VNTR on measures of in vitro DAT expression and pharmacology. A series of four DAT1 constructs, each containing the DAT1 coding region, but varying with respect to the downstream presence or content of the 3'UTR, were engineered and stably transfected into an HEK-293 variant using Flp-In integration, an enzyme-mediated, site-specific recombination technology.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 1 2 1 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 143 148 143 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 188 193 188 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 226 230 226 230 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max </sub>
###xml 317 322 317 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 541 546 541 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
[3H] Win 35,428 saturation binding assays and DAT immunoblots revealed statistically significant differences in DAT expression attributable to DAT1 genotype. Cells harboring the 10-repeat DAT1 variant were characterized by a Bmax approximately 50% greater than cells with the 9-repeat VNTR; those containing only the DAT1 coding region or the coding region flanked by a truncated 3' UTR resulted in greater DAT density than either of the naturalistic 9- and 10-repeat variants. Competition binding assays showed no statistically significant DAT1 genotype effects on the DAT affinity for methylphenidate, a finding consistent with the positional location of the VNTR.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 26 31 26 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
This study identified the DAT1 VNTR as a functional polymorphism and provides an interpretive framework for its association with behavioral phenotypes.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 67 68 67 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 71 73 71 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 223 228 223 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 234 240 234 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC6A3</italic>
###xml 306 307 306 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 365 370 365 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 404 405 404 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 452 455 452 455 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 504 505 504 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 506 507 506 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 656 657 656 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 658 659 658 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 860 861 860 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 862 864 862 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1102 1104 1102 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1105 1107 1105 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 576 581 <span type="species:ncbi:9606">human</span>
###xml 759 765 <span type="species:ncbi:9606">humans</span>
###xml 767 778 <span type="species:ncbi:9598">chimpanzees</span>
###xml 845 848 <span type="species:ncbi:10116">rat</span>
###xml 853 858 <span type="species:ncbi:10090">mouse</span>
The human dopamine transporter (hDAT), one member of a family of Na+/Cl- dependent transmembrane transport proteins, serves as a critical regulator of dopaminergic neurotransmission throughout much of the brain. The ~64 kb DAT1 gene (SLC6A3) that encodes the DAT includes 15 exons separated by 14 introns [1]. Concurrent with the cloning and chromosomal mapping of DAT1 to the short arm of chromosome 5 [2], a VNTR polymorphism was identified in the 15th exon, a region encoding the transcript's 3' UTR [3,4]. The 40-bp VNTR element is repeated between 3-13 times and in most human populations occurs with greatest frequency in the 9- and 10-repeat forms [5-7]. This polymorphic variation may be evolutionarily young, as a VNTR homologue has been observed in humans, chimpanzees, and cynomologus macaques, but not in lower mammals including the rat and mouse [8-10]. Though the VNTR resides in the 3'UTR and therefore does not affect the protein's amino acid sequence, regulatory factors such as mRNA stability and nuclear transport, and protein synthesis are potentially regulated by such variations [11-14].
###end p 9
###begin p 10
###xml 93 98 93 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 182 191 182 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 218 220 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 226 234 226 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 450 455 450 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 592 594 592 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 651 652 651 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 782 787 782 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
Given the prominent role of dopamine neurotransmission in normal and abnormal behaviors, the DAT1 VNTR became the object of numerous genetic linkage and association studies [15-20], in vitro reporter gene experiments [21-26], in vivo SPECT molecular imaging studies [27-30], and pharmacogenetic examinations of the well-documented inter-individual variation in the response to treatment with DAT inhibitors [31-34]. Reports of the association of the DAT1 VNTR with ADHD have garnered particular attention, with the balance of evidence relating the 10-repeat VNTR to symptoms of the disorder [35]. Despite its high frequency in the general population [7] and an absence of studies addressing possible effects of the VNTR on measures of DAT physiology and pharmacology, the 10-repeat DAT1 allele has become generally recognized as a "high risk" allele for ADHD.
###end p 10
###begin p 11
###xml 88 97 88 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 209 214 209 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 262 267 262 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 398 403 398 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 561 563 561 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 623 648 623 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Saccharomyces cerevisiae </italic>
###xml 907 916 907 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 941 946 941 946 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 976 978 976 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 623 647 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
The present study utilized radioligand binding and immunoblotting techniques to compare in vitro DAT density and ligand affinity across a series of cell lines stably transfected with constructs containing the DAT1 coding region flanked downstream by one of four DAT1 3'UTR variants. Flp-mediated recombination, one of a family of site-specific recombination technologies, was used to integrate the DAT1 constructs into a common, transcriptionally-active region of the genome, eliminating several caveats associated with traditional reporter gene methodologies [36]. Flp recombinase, the enzymatic basis of the system, is a Saccharomyces cerevisiae derived enzyme that utilizes a substrate Flp recombination target (FRT) sequence upstream of a gene of interest (GOI) to site-specifically insert the GOI into a target site in a host cell line, thereby providing a well-controlled approach to establishing the in vitro functional effect of the DAT1 VNTR polymorphism on the DAT [37].
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
DAT binding assays
###end title 13
###begin p 14
###xml 30 31 30 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 138 142 138 142 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max </sub>
###xml 158 163 158 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 185 186 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 238 243 238 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 292 295 292 295 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 353 358 353 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 406 415 406 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 475 480 475 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 605 609 605 609 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max </sub>
###xml 705 706 705 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 706 708 706 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d </italic>
###xml 706 708 706 708 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>d </italic></sub>
###xml 730 735 730 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 873 874 873 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 895 896 895 896 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1052 1057 1052 1057 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 1108 1109 1108 1109 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 1144 1145 1144 1145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 1149 1151 1149 1151 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
Results of three independent [3H] Win 35,428 saturation binding experiments revealed statistically significant (p < 0.05) differences in Bmax attributable to DAT1 VNTR genotype (Figure 2). Membranes from cells stably transfected with the DAT1 coding region (hDAT) displayed the highest mean Bmax. Extension of hDAT with the most proximal ~800 bp of the DAT1 3'UTR (hDAT Zero) was associated with decreased in vitro DAT density compared to the hDAT line. Of the two prevalent DAT1 VNTR variants (hDAT 9 and hDAT 10), cells stably transfected with construct harboring the 10-repeat allele displayed a mean Bmax 54% greater than those harboring the 9-repeat variant. Statistically significant differences in Kd were observed between DAT1 variants in saturation binding assays, though the magnitude of the effect was modest and considered physiologically insignificant (Figure 3); goodness of fit (R2) exceeded 0.98 for all non-linear regressions. Three independent competition binding experiments also revealed no pharmacologically significant effects of DAT1 genotype on methylphenidate's ability to displace [3H] Win 35,428 from the DAT (Figure 4). R2 values were >/= 0.95 for all competition binding curves.
###end p 14
###begin p 15
###xml 11 16 11 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 76 80 76 80 <bold xmlns:xlink="http://www.w3.org/1999/xlink">hDAT</bold>
###xml 82 87 82 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 182 191 182 191 <bold xmlns:xlink="http://www.w3.org/1999/xlink">hDAT Zero</bold>
###xml 220 225 220 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 325 331 325 331 <bold xmlns:xlink="http://www.w3.org/1999/xlink">hDAT 9</bold>
###xml 354 359 354 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 448 455 448 455 <bold xmlns:xlink="http://www.w3.org/1999/xlink">hDAT 10</bold>
###xml 478 482 478 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1</italic>
Summary of DAT1 constructs used in Flp-In recombination protocol. Top left: hDAT, DAT1 coding region necessary and sufficient to produce a functional transporter protein. Top right: hDAT Zero, a construct containing the DAT1 coding region flanked by an ~800 bp fragment of the 3'UTR upstream of the VNTR region. Bottom left: hDAT 9, a construct with the DAT1 coding region upstream of a full length 3'UTR harboring the 9-repeat VNTR. Bottom right: hDAT 10, a construct with the DAT1 coding region upstream of a full length 3'UTR containing the 10-repeat VNTR.
###end p 15
###begin p 16
###xml 104 105 104 105 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 164 168 164 168 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max </sub>
###xml 184 189 184 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 274 275 274 275 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
Comparative influence of 3'UTR variation on DAT saturation binding across three independent replicates. A) A characteristic binding curve revealing differences in Bmax attributable to DAT1 genotype. Mock-transfected negative control cells displayed no specific DAT binding. B) A one way ANOVA with Holm-Sidak post-hoc analysis demonstrated genotype-dependent differences in DAT density for all multiple comparisons (* = p < 0.05).
###end p 16
###begin p 17
###xml 5 6 5 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 6 8 6 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d </italic>
###xml 6 8 6 8 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>d </italic></sub>
###xml 53 54 53 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
Mean Kd measurements derived from three independent [3H] Win 35,428 saturation binding assays. A one way ANOVA with Holm-Sidak post-hoc analysis detected VNTR-dependent differences in the DAT ligand affinity (* = p < 0.05) for all but the hDAT-vs-hDAT9 compairson.
###end p 17
###begin p 18
###xml 102 107 102 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
Representative Competition Binding Curves. No pharmacologically significant differences exist between DAT1 variants in the encoded protein's affinity for methylphenidate.
###end p 18
###begin title 19
DAT western blots
###end title 19
###begin p 20
###xml 118 122 118 122 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max </sub>
###xml 196 201 196 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 220 221 220 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
The observed rank order of immunoblotted DAT signal intensity across three independent replicates paralleled that of Bmax values derived from saturation binding experiments for the four different DAT1 constructs (Figure 5). Mock transfected cells displayed no DAT immunoreactivity. Uniformity of 14-3-3beta immunoreactivity between the different transfected cell lines confirmed near equivalent between-lane protein loading and served as a basis for normalization. Significant differences (p < 0.05) were detected for all comparisons except hDAT 10-vs-hDAT Zero.
###end p 20
###begin p 21
###xml 110 111 110 111 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 709 710 703 704 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 356 359 <span type="species:ncbi:10116">rat</span>
###xml 609 612 <span type="species:ncbi:10116">rat</span>
###xml 689 695 <span type="species:ncbi:9986">rabbit</span>
Results of western analysis support the rank order of DAT density observed in saturation binding experiments. A) Lane 1: molecular weight marker, Lane 2: negative control, Lane 3: hDAT transfected cell line, Lane 4: hDAT Zero transfected cell line, Lane 5: hDAT 9 transfected cell line, Lane 6: hDAT 10 transfected cell line. Blots were probed both with a rat anti-DAT monoclonal antibody specific for the transporter's N-terminal region as well as a 14-3-3beta polyclonal antibody to control for possible protein loading differences. DAT immunoreactivity was detected with an Alexa Fluor 680 conjugated anti-rat IgG (red) and 14-3-3beta immunoreactivity with an IRDye-800 conjugated anti-rabbit IgG (green). B) DAT immunoreactivity was normalized to the 14-3-3beta signal, densiometrically quantified with respect 14-3-3beta content, and analyzed via a one way ANOVA with a Holm-Sidak post-hoc analysis. Statistically significant differences (* = p < 0.05) were detected for all comparisons except the hDAT10-vs-hDAT Zero comparison.
###end p 21
###begin title 22
Discussion
###end title 22
###begin p 23
###xml 25 29 25 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1</italic>
###xml 621 623 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 752 757 752 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 857 866 857 866 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 883 885 883 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 886 888 886 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 928 930 928 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1107 1109 1107 1109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1168 1177 1168 1177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1194 1199 1194 1199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
The VNTR polymorphism of DAT1, though residing outside the gene's coding region, is of interest due to its possible influence on the regulation of dopaminergic neurotransmission, its implication in conferring genetic vulnerability for ADHD, and its putative role in modulating response to treatment with a first line medication, methylphenidate. The VNTR has not, however, been characterized as regards its possible influence on DAT physiology and pharmacology. Accumulating evidence that the 3'UTR influences the nuclear export, polyadenylation, subcellular targeting and rates of transcription and degradation of mRNA [11] supports the possibility that a VNTR polymorphism in this region could exert a regulatory influence on gene function. Observed DAT1 VNTR effects on reporter gene expression have provided initial support for an effect of the VNTR on in vitro gene expression [21-26], though the results vary widely (see [25] for discussion). Furthermore, heterologous reporter gene methodologies are subject to context-specific effects that may not reflect a sequence's impact on a gene of interest [38]. The present study provides multiple lines of converging in vitro evidence for the DAT1 VNTR's modulatory effect on DAT expression, thus supporting it as a functional polymorphism that may contribute to the recognized inter-individual differences in DAT density and dopaminergic function.
###end p 23
###begin p 24
###xml 124 128 124 128 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max </sub>
###xml 133 134 133 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 229 233 229 233 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max </sub>
###xml 238 239 238 239 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 354 359 354 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 380 385 380 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 535 539 535 539 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max </sub>
###xml 691 693 691 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 694 696 694 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 782 787 782 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 951 956 951 956 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 958 961 958 961 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
The hDAT cell line, which lacks a 3'UTR altogether, displayed the highest overall DAT density and immunoreactivity, with a Bmax for [3H] Win 35,428 binding roughly 2.5-fold that of the hDAT 9 line. The hDAT Zero cell line had a Bmax for [3H] Win 35,428 binding ~25% less than that of the hDAT construct, a result that implicates the first ~800 bp of the DAT1 3'UTR in diminishing DAT1 transcription, mRNA stability, or translation. The additional extension of the 3'UTR to include either the 9 or 10 repeat variant further attenuated Bmax and DAT immunoreactivity compared to that for the hDAT and hDAT Zero cell lines. These results are consistent with the results of reporter gene assays [13,25] in which constructs containing the VNTR polymorphism were associated with decreased DAT1 expression. Incremental attenuation of DAT density by both the ~800 bp fragment and the VNTR region suggests the presence of at least two regulatory regions in the DAT1 15th exon, with the differential effects of the 9- and 10-repeat variants possibly due to interactions between a VNTR-specific attenuator and one contained within the ~800 bp fragment.
###end p 24
###begin p 25
###xml 89 94 89 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 95 96 95 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 97 98 97 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 419 421 419 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 524 533 524 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
Comparison of the 9- and 10-repeat variants, the two most frequent allelic variations of DAT1 [5,7] revealed that DAT binding site density for the 10-repeat VNTR was elevated approximately 50% over that of the 9-repeat allele, with western analysis confirming this finding. This result indicates that the 3'UTR does not simply mediate a length-dependent reduction in DAT availability, as has been previously suggested [22]. Rather, variation in the number of tandem repeats appears to have distinct modulatory influences on in vitro DAT density.
###end p 25
###begin p 26
###xml 35 44 35 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 104 109 104 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 253 258 253 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 703 705 703 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 853 858 853 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 1105 1107 1105 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1283 1285 1283 1285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1560 1565 1560 1565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 776 781 <span type="species:ncbi:9606">human</span>
###xml 839 844 <span type="species:ncbi:9606">human</span>
At least five groups have reported in vitro reporter gene results examining the relative effects of the DAT1 9- and 10-repeat VNTR's influence on luciferase or GFP expression in transiently transfected systems. Fuke and coworkers compared the impact of DAT1 3'UTRs containing the 7-, 9- and 10-repeat alleles on luciferase reporter activity [21]. Their results suggested that the 10-repeat allele yielded the greatest reporter gene expression. Additionally, it was found that constructs harboring the VNTR polymorphism (of any variety) resulted in lower reporter gene expression than those with no repeat region; our data largely concurs with these observations. However, Inoue-Murayama and colleagues [22], who assessed the relative luciferase activities associated with the human 9-, 10- and 11-repeat alleles in addition to several non-human primate DAT1 VNTRs, reported an inverse relationship between reporter gene activity and repeat number, an observation consistent with possible length-dependent reductions in transfection efficiency, and a finding that differs from our data. Miller and Madras [26] arrived at similar findings (i.e. 9 > 10), though their analysis suggested that an additional SNP located in the 3'UTR may further regulate the VNTR's effects. Lastly, Mill [25], who recently published a well-controlled set of reporter gene analyses using both neuronal and non-neuronal cell lines, found no significant difference in reporter gene activity attributable to VNTR copy number. These discrepant studies underscore the need to examine the DAT1 VNTR effects under carefully controlled experimental conditions using the DAT protein itself as the reporter signal.
###end p 26
###begin p 27
###xml 563 565 563 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 566 568 566 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1002 1007 1002 1007 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
The veracity of our findings is reinforced by the use of a targeted stable integration protocol that eliminates confounds to construct comparison attributable to variable transfection efficiency or clonal variance, both common pitfalls of transient transfection or conventional non-targeted stable integration approaches. Unlike typical stable integration methods, the enzymatically-mediated Flp-In system employed herein resulted in DAT-expressing cell lines with their respective constructs directionally integrated at a common, transcriptionally-active locus [39-41]. pcDNA5/FRT's hygromycin resistance gene, which was used in the isolation and expansion of cell lines for this study, lacks both a promoter and start codon, thereby preventing selection in instances of random genomic insertion. When enzymatically integrated into the host cell line, however, the gene becomes properly aligned with both a promoter and initiation sequence, permitting expression of the hygromycin resistance gene and DAT1 variant from a common site. This targeted stable integration approach eliminates the need to normalize data to account for differential transfection efficiency, a significant confound of most traditional reporter gene methodologies.
###end p 27
###begin p 28
###xml 92 100 92 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 107 110 107 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink">123</sup>
###xml 164 169 161 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 234 236 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 237 239 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 438 440 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 660 662 657 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 675 677 672 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 727 729 724 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 748 751 745 748 <sup xmlns:xlink="http://www.w3.org/1999/xlink">123</sup>
###xml 1238 1241 1232 1235 <sup xmlns:xlink="http://www.w3.org/1999/xlink">123</sup>
###xml 1456 1458 1447 1449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1459 1461 1450 1452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 1519 1524 1510 1515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 1606 1609 1597 1600 <sup xmlns:xlink="http://www.w3.org/1999/xlink">123</sup>
###xml 1711 1713 1699 1701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 1724 1727 1712 1715 <sup xmlns:xlink="http://www.w3.org/1999/xlink">123</sup>
###xml 2032 2034 2017 2019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 2053 2061 2038 2046 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 2104 2113 2089 2098 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 2128 2133 2113 2118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 2175 2183 2160 2168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 100 105 <span type="species:ncbi:9606">human</span>
The current findings are particularly interesting considering the divergent results of four in vivo human [123I] beta-CIT SPECT studies examining the impact of the DAT1 VNTR polymorphism on measures of striatal DAT binding potential [27-30]. The first study, conducted in a mixed population of abstinent alcoholics and healthy controls, found that 10-repeat homozygotes displayed a 22% higher DAT binding density than 9/10 heterozygotes [29]. A similar study conducted in a population of healthy subjects revealed sharply different results, with 10-repeat homozygotes characterized by striatal DAT binding 13.4% lower than subjects carrying a 9-repeat allele [28]; van Dyck [30] recently arrived at similar findings. Martinez [27], also utilizing [123I] beta-CIT, studied a mixed population of 59 healthy controls and schizophrenics and found no difference in binding potential between 10-repeat homozygotes and carriers of the 9-repeat allele. Though these studies differ widely in their conclusions, a number of factors may have contributed to the varied results. Foremost, subject populations varied from healthy individuals to those with psychiatric diagnoses characterized by probable dopaminergic dysregulation. Second, the use of [123I] beta-CIT, a high affinity DAT ligand, but one lacking selectivity for the DAT over the serotonin transporter, highlights the need to conduct experiments using more selective ligands, preferably in a PET setting [42,43]. Third, two of these studies focused exclusively on the DAT1 VNTR polymorphism and did not consider other polymorphisms capable of modulating [123I] beta-CIT binding (e.g. SERT promoter VNTR polymorphism known to modulate 5-HT transporter density [44]); given [123I] beta-CIT's binding profile and the partially overlapping brain regional distribution of DAT and SERT, a portion of the between-study variance may be attributable to variations in genes encoding other monoamine transporters. In light of these limitations, PET imaging with highly selective DAT ligands [45] remains the best in vivo approach to assessing whether the observed in vitro effects of the DAT1 VNTR on DAT expression generalizes to the in situ DAT.
###end p 28
###begin p 29
###xml 110 111 110 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
Of interest are the small, though statistically significant, effects of 3'UTR variations on DAT affinity for [3H] Win 35,428. Given the location of the VNTR polymorphism, genotype-dependent variations in the DAT affinity would not be predicted. Preliminary data from our laboratory suggests that VNTR-dependent rates of DAT protein glycosylation may account for the observed variance in ligand affinity, a hypothesis subject to ongoing testing in our laboratory.
###end p 29
###begin p 30
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 286 295 286 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 342 350 342 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 435 444 435 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 479 487 479 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 633 635 633 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 636 638 636 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 1122 1127 1122 1127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 1139 1141 1139 1141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1142 1144 1142 1144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1342 1344 1342 1344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1451 1456 1451 1456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 1563 1568 1563 1568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 1192 1195 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1399 1402 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
While the present study provides evidence supporting the DAT1 VNTR as a functional polymorphism, the strength of this assertion is tempered by the inherent limitations of the experimental approach. First, despite the magnitude and reproducibility of the observed effects in the present in vitro study, these effects may not generalize to the in vivo condition. The association of the 10-repeat allele with an increase in the amount of in vitro DAT protein could be attenuated by in vivo counter-regulatory mechanisms including upregulation of lysosomal DAT targeting and modulation in rates of endosome-mediated DAT internalization [46-48]. The current experiments, conducted in membrane homogenates, do not discriminate between DAT proteins functionally inserted into the cell membrane and those contained within cellular vesicles. Secondly, the scope of the present study was limited to the effects of the VNTR region independent of other SNP or haplotype effects that may contribute to variability in dopaminergic function; our experiments, by design, do not reflect the recognized complexity of interactions affecting DAT1 expression [17,24]. Third, our experiments utilized the powerful CMV promoter; while the use of strong viral promoters is common in experiments such as this, possible promoter/VNTR interactions have been suggested [26]. Therefore, different effects may be observed if the CMV promoter was substituted with either the native DAT1 promoter or a weaker constitutively active sequence. Lastly, our results are limited to the effects of the DAT1 VNTR in Flp-In 293 cells, a cell line that may lack certain tissue-specific regulatory factors found in DAT rich tissues. While it would be of interest to study these effects in dopaminergic neurons in combination with Flp-In integration, such an approach would render it difficult to pharmacologically distinguish between native and transfected DAT and would significantly compromise the otherwise high degree of experimental control characteristic of the present experiments.
###end p 30
###begin p 31
###xml 11 16 11 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 113 118 113 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 245 250 245 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 418 423 418 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 741 743 741 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 744 746 744 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
Though the DAT1 3'UTR is lengthier than the transcript's entire coding region, is a likely target for modulating DAT1 translation, and has been associated with symptoms of ADHD, there exists the possibility of linkage disequilibrium between the DAT1 3'UTR and a separate, yet unidentified, causal genetic element. Still, these findings have interpretive significance to the often-observed association of the 10-repeat DAT1 VNTR with ADHD. ADHD is viewed as being related to a deficit in synaptic dopamine subserving task-specific signaling. An increase in DAT expression in 10-allele carriers could result in such a dopamine deficit state, depleting dopamine's ability to task-specifically increase signal to noise ratios in target neurons [49,50] and result in deficits in attention and impulse control.
###end p 31
###begin title 32
Methods
###end title 32
###begin title 33
###xml 11 16 11 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
Cloning of DAT1 variants
###end title 33
###begin p 34
###xml 5 10 5 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 592 597 592 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 721 738 721 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">Additional file 1</xref>
###xml 821 822 821 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
Four DAT1 constructs were created, each containing a common promoter, coding region, and poly (A) tail, but varying with respect to the presence and length of the 3'UTR. All constructs were restriction mapped and sequence verified throughout the length of the insert prior to targeted stable transfection in Flp-In 293 cells. Though the sequence of these clones is nearly indistinguishable from that predicted by public genomic databases, they are not eligible for Genbank submission due to the mixed origin (cDNA and genomic DNA) of the constructs. Since the sequence variance in and around DAT1 is complex, we have included as supplemental material to this manuscript the complete annotated sequence of each construct (Additional file 1). The constructs, presented in order of increasing length, are depicted in Figure 1 and were generated as follows:
###end p 34
###begin title 35
hDAT
###end title 35
###begin p 36
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 344 349 344 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 605 610 605 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 8 11 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
The pRC/CMV plasmid (Invitrogen, Carlsbad, California, USA) containing the DAT1 coding region was obtained (courtesy of Dr. Marc Caron, Duke University) and the insert released via digestion with PmeI (New England Biolabs, Beverly, MA, USA). The resultant fragments were electrophoretically resolved on 1.5% agarose and the band containing the DAT1 coding region was purified using the QIAquick Gel Extraction Kit (Qiagen, Venlo, The Netherlands). Similarly, pcDNA5/FRT was digested with PmeI, the vector backbone purified (QIAquick PCR Purification Kit) and treated with shrimp alkaline phosphatase. The DAT1 insert underwent blunt end ligation into the pcDNA5/FRT backbone by overnight reaction at 14degreesC with T4 DNA ligase (New England Biolabs).
###end p 36
###begin title 37
hDAT Zero
###end title 37
###begin p 38
###xml 26 31 26 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 221 225 221 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1</italic>
###xml 264 268 264 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1</italic>
###xml 994 999 988 993 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 1072 1077 1066 1071 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 142 147 <span type="species:ncbi:9606">human</span>
###xml 952 955 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
An ~800 bp segment of the DAT1 3'UTR beginning upstream of the stop codon and terminating proximal to the VNTR element was cloned from banked human DNA into pCR 2.1 TOPO using the TOPO TA Cloning Kit (Invitrogen). Oligos DAT1E15F (5'-CAACCACAGTCTCGCGGCTTT-3') and DAT1E15ZeroR (5'CTCAGGCCGTTCCCTACACC-3') were used in conjunction with Platinum Pfx DNA Polymerase (Invitrogen) to drive 35 cycles of PCR using the manufacturer's recommended protocol. Following initial amplification, 1 U of Taq polymerase was added to the reaction mixture and incubated at 72degreesC for 10 minutes; the resultant PCR product with 3' A-overhangs was used immediately in a TOPO-TA cloning reaction. After transforming competent bacteria and identifying clones containing the insert of interest, the fragment containing the 3'UTR was released via restriction digestion with BsmBI and XbaI (New England Biolabs), band purified, and cloned into a BsmBI/XbaI site in the pRC/CMV plasmid immediately downstream of the DAT1 coding region. The resultant clone contained an insert consisting of the DAT1 coding region flanked by a ~800 bp fragment of the 3'UTR up to, but not including, the VNTR region. This construct was subcloned into the pcDNA5/FRT plasmid via the same blunt end cloning method used in the generation of the hDAT plasmid.
###end p 38
###begin title 39
hDAT9 and hDAT10
###end title 39
###begin p 40
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 11 14 11 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 203 207 203 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1</italic>
###xml 244 248 244 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1</italic>
###xml 786 787 786 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1143 1148 1143 1148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 1071 1074 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
The DAT1 15th exon from a previously genotyped 9/10 heterozygote was PCR amplified and cloned into pCR2.1-TOPO using a protocol similar to that used in the generation of the hDAT Zero construct. Primers DAT1E15F (sequence previously noted) and DAT1E15R (5'-AGGGACCCACACGATGCTGA-3') were used to produce a ~2100 bp PCR product that was subsequently made TOPO-TA compatible through the previously described A-overhang procedure. TOPO-TA reactions were immediately performed and used to transform competent bacteria. Ampicillin-resistant bacterial colonies were isolated and grown overnight using standard culture conditions. Plasmid DNA was isolated and genotyped to differentiate those containing the 9-repeat versus the 10-repeat VNTR via a protocol that has been previously described [4]. Following identification of clones containing the 9 and 10 repeat VNTRs, respectively, the insert containing the entire 3'UTR was released via restriction digestion with BsmBI and XbaI. The band was purified via gel extraction and cloned into a BsmBI/XbaI site in the original pRC/CMV plasmid. The resultant clones contained an insert consisting of the DAT1 coding region flanked by a ~1900 bp fragment of the 3'UTR harboring either the 9 or 10 repeat variant. The insert was subcloned into the pcDNA5/FRT plasmid via the previously described protocol.
###end p 40
###begin title 41
Creation and maintenance of stably transfected model cell system
###end title 41
###begin p 42
###xml 294 295 287 288 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 517 522 510 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 644 646 637 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 833 838 824 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
###xml 1943 1944 1924 1925 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 2037 2038 2018 2019 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 2286 2288 2261 2263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g </italic>
###xml 2417 2419 2386 2388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g </italic>
The Flp-In 293 host cell line (Invitrogen), an HEK-293 variant containing a Flp-In recombination site at a transcriptionally active locus, was grown in complete medium (D-MEM with 2 mM L-glutamine, 10% FBS, 1% penn/strep) supplemented with 100 mug/mL Zeocin in a 37degreesC incubator with 5% CO2. 48-hours prior to transfection, cells were split into 6-well plates and grown to ~80% confluence on the day of transfection and incubated in complete medium lacking Zeocin. Cells were co-transfected with one of the four DAT1 variants and pOG44 (Invitrogen), a plasmid encoding the Flp-recombinase enzyme necessary for targeted stable integration [51]. The Lipofectamine 2000 reagent was used to transfect the cells according to the manufacturer's recommended protocol (Invitrogen). Briefly, 3.6 mug pOG44 and 0.4 mug of one of the four DAT1 constructs were diluted to a 250 mul volume in Opti-MEM reduced serum media (Invitrogen); similarly, 10 muL Lipofectamine 2000 was diluted to a volume of 250 muL and incubated at room temperature for 5 minutes. The diluted DNA and Lipofectamine solutions were combined and incubated at room temperature for 20 minutes and then added to culture medium. 24-hours after transfection, cells were washed with PBS and fresh complete medium was again added. 48-hours after transfection, cells were split into fresh medium, plated on 150 mm x 25 mm cell culture dishes, and incubated at 37degreesC until cells attached. Medium was then removed and replaced with complete medium supplemented with the selecting antibiotic hygromycin (100 mug/mL). Selective media was replaced every 4 days until hygromycin-resistant foci were identified. Single resistant colonies were encircled with a cloning cylinder, dislodged with 0.25% trypsin, and expanded. Cells exhibiting the phenotype for proper Flp-In recombination and demonstrating the presence of a cocaine-sensitive DAT as assessed by a rapid single concentration [3H] dopamine uptake assay were selected; clones were expanded to confluence in 2-tray (1264 cm2) Nunc Cell Factories (Nalge Nunc International, Rochester, NY, USA). Once confluent, the four cell lines were harvested with 37degreesC PBS containing 0.53 mmol/L ethylenediaminetetraacetic acid, separated into aliquots, and centrifuged at 2000 x g for 10 min. Supernatants were decanted and the pellets were rinsed with 37degreesC PBS. Pellets were again centrifuged at 2000 x g for 10 min, the supernatants decanted, and the pellets stored at -80degreesC until the time of assay. Mock transfected cells were confirmed to have no specific DAT binding or immunoreactivity prior to initiation of assays.
###end p 42
###begin title 43
General radioligand binding methods
###end title 43
###begin p 44
###xml 407 408 404 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 604 605 597 598 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 654 658 646 650 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-10 </sup>
###xml 663 666 655 658 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
Binding assays were carried out in 0.03 M phosphate buffer (pH 7.4) containing 0.32 M sucrose. Membrane suspensions were prepared by resuspending the pellet in 7 mL of ice cold assay buffer followed by homogenization with a Polytron PT3000 for 20 seconds at 20,000 rpm. All assays were performed in 12 x 75 mm polystyrene tubes in a 1,000 muL final volume consisting of 800 muL of assay buffer, 100 muL of [3H] Win 35,428 (Perkin Elmer, Boston, MA), and 100 muL of cell membrane suspension. Competition assays were performed in a final volume of 1,000 mul consisting of 700 mul assay buffer, 100 muL of [3H] Win 35,428, 100 muL of methylphenidate HCl (10-10 to 10-6 M) (Sigma-Aldrich, St. Louis, MO), and 100 mul of cell suspension. Nonspecific binding was defined via the addition of 25 muM cocaine HCl (Sigma-Aldrich). Incubations were terminated via rapid vacuum filtration through GF/B filters presoaked in assay buffer containing 0.3% polyethyleneimine and rinsed with three washes (5 mL) of ice cold assay buffer. Filters were punched, placed in scintillation vials, and equilibrated overnight in 6 mL of liquid scintillation cocktail (Ultima Gold, Packard, Meriden, CT, USA). Vials were shaken and radioactivity determined in a liquid scintillation counter at 50% efficiency for 240 sec/vial.
###end p 44
###begin title 45
Saturation binding assays
###end title 45
###begin p 46
###xml 21 22 21 22 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 373 374 371 372 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
The DAT radioligand [3H] Win 35,428 was isotopically diluted with freshly weighed cold ligand (courtesy of Dr. Michael Kuhar, Emory University) in silanized borosilicate glass tubes. Drug was initially dissolved in assay buffer containing 5 mmol/L HCl at a concentration of 1 mug/muL followed by serial dilution with assay buffer. Saturation binding assays utilized final [3H] Win 35,428 concentrations over a range of 0.5 to 75 nM. Total and nonspecific binding was determined in triplicate at each concentration of ligand. Assays were initiated by the addition of membrane suspension and incubated at 4degreesC for 4 hours.
###end p 46
###begin title 47
Competition binding assays
###end title 47
###begin p 48
###xml 1 2 1 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 214 215 214 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 215 217 215 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d </italic>
###xml 215 217 215 217 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>d </italic></sub>
###xml 222 223 222 223 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
[3H] Win 35,428 was isotopically diluted with freshly weighed cold ligand in silanized borosilicate glass tubes as previously described. The concentration used in competition assays (5.85 nM) approximated the mean Kd for [3H] Win 35,428 binding to the DAT from the binding site saturation studies. Methylphenidate was dissolved in assay buffer containing 5 mmol/L HCl at an initial concentration of 1 mug/mul. The concentrated solution subsequently underwent serial dilution to generate final concentrations of competing ligand ranging from 0.01 to 10,000 nM. Assays were initiated by the addition of membrane suspension, and incubated at 25degreesC for 1 hour.
###end p 48
###begin title 49
Protein assays
###end title 49
###begin p 50
At the time of each saturation binding assay, twelve 100 muL aliquots of each membrane homogenate were collected for purposes of measuring total mean protein content with a BCA protein assay (Pierce Biotechnology, Rockford, IL, USA). Protein assay results were used in the normalization of saturation binding data to account for minor differences in total added tissue.
###end p 50
###begin title 51
Western blots
###end title 51
###begin p 52
###xml 741 758 740 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">Additional file 2</xref>
###xml 1154 1157 <span type="species:ncbi:10116">rat</span>
###xml 1297 1303 <span type="species:ncbi:9986">rabbit</span>
###xml 1543 1546 <span type="species:ncbi:10116">rat</span>
###xml 1617 1623 <span type="species:ncbi:9986">Rabbit</span>
Cell pellets were homogenized in PBS in the presence of DNAse and protease inhibitors (Roche Applied Science, Indianapolis, IN, USA). Samples were then enzymatically deglycosylated (Enzymatic Protein Deglycosylation Kit, Sigma-Aldrich) prior to the loading and electrophoretic resolution of 20 mug total protein in sample buffer (40 mM Tris, pH 6.8, 0.1% SDS, 10% glycerol, 0.025% Bromphenol blue) on 10% acrylamide. DAT, a highly glycosylated protein, typically runs as a smear of high molecular weight bands; deglycosylation reduces the core protein to a mass of ~50 kD and greatly aids densitometry analysis. An example of mature, fully-glycosylated DAT and the resultant high molecular weight smear is included as supplemental material (Additional file 2) to demonstrate the significant benefit of sample deglycosylation. BioRad's Precision Plus Protein Standards (Hercules, CA, USA) were loaded into the first lane of each gel. Gels were transferred to PVDF membranes (Millipore, Billerica, MA, USA) overnight at 3 mA. Membranes were blocked for 1 hour at RT (SuperBlock Blocking Buffer, Pierce Biotechnology) on an orbital shaker and probed with a rat anti-DAT monoclonal antibody specific for the protein's N-terminal region (1:250 dilution, courtesy Dr. Allan Levey, Emory University) and rabbit anti 14-3-3beta polyclonal antibody (1:500 dilution, Santa Cruz Biotechnology, Santa Cruz, CA, USA) at room temperature for 1 hour. Following rinsing, the blot was incubated with a 1:10,000 dilution of both Alexa Fluor 680 conjugated anti-rat IgG (Molecular Probes, Eugene, OR, USA) and IRDye-800 conjugated Anti-Rabbit IgG (Rockland Immunochemicals, Gilbertsville, PA, USA) for 1 h at room temperature. Blots were rinsed, dried and visualized using a LI-COR Biosciences Odyssey Infrared imager (Lincoln, NE, USA). The ubiquitously expressed 14-3-3beta was used as a protein loading control. Western analyses were conducted in triplicate.
###end p 52
###begin title 53
Data analysis
###end title 53
###begin title 54
Radioligand binding data
###end title 54
###begin p 55
###xml 171 172 171 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 172 173 172 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 172 173 172 173 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>d</italic></sub>
###xml 176 180 176 180 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max </sub>
###xml 184 185 184 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 185 187 185 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i </italic>
###xml 185 187 185 187 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>i </italic></sub>
###xml 233 234 231 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
Saturation and competition binding curves were analyzed by the iterative, non-linear, curve fitting program Prism 4.0 (GraphPAD Software, Inc., San Diege, CA). Values for Kd, Bmax and Ki are expressed as mean values +/- S.E.M (Table 1). A one-way ANOVA with a Holm-Sidak post-hoc analysis was used to identify statistically significant differences between VNTR variants. The threshold for statistical significance was set at p < 0.05.
###end p 55
###begin p 56
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 44 49 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
In vitro pharmacological characteristics of DAT1 variants.
###end p 56
###begin title 57
Western blot analysis
###end title 57
###begin p 58
###xml 288 293 285 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
Western blots underwent densitometric analysis using the program ImageJ 1.33 u (National Institutes of Health, Bethesda, Maryland, USA). The DAT signal was normalized to the 14-3-3beta signal within each lane (expressed in arbitrary units), then subsequently examined for main effects of DAT1 genotype via a one way ANOVA with a Holm-Sidak post hoc comparison. The threshold for statistical significance was set at p < 0.05.
###end p 58
###begin title 59
Authors' contributions
###end title 59
###begin p 60
SHV performed all molecular biology, radioligand binding experiments, immunoassays, statistical analysis and drafted the manuscript. MJO participated in the design of the pharmacological aspects of the study, provided supervision of radioligand binding experiments, and aided in the revision of the manuscript. CDK participated in the overall design and coordination of the study and aided in the drafting of the manuscript. All authors read and approved the final manuscript.
###end p 60
###begin title 61
Supplementary Material
###end title 61
###begin title 62
Additional File 1
###end title 62
###begin p 63
###xml 85 90 85 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
ZIP archive containing full length annotated sequence files (.gb format) of the four DAT1 constructs. dat1_clones_in_pcDNA5-FRT.zip (17 K)
###end p 63
###begin p 64
Click here for file
###end p 64
###begin title 65
Additional File 2
###end title 65
###begin p 66
Western blot run without sample deglycosylation. Samples are variably glycosylated, creating a high molecular weight smear. Sample deglycosylation yields tight, discrete bands that are more easily analyzed.
###end p 66
###begin p 67
Click here for file
###end p 67
###begin title 68
Acknowledgements
###end title 68
###begin p 69
###xml 82 87 82 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAT1 </italic>
The authors would like to acknowledge Dr. Marc Caron for generously supplying the DAT1 starting material, Dr. Allan Levey and Mr. Craig Heilman for assistance with DAT western blots, Dr. Michael Kuhar for advice, and Elyse Katz and Dina Ghoneim for technical assistance. This work was supported by the National Institute of Mental Health (R21 MH067939) and by the National Institute on Drug Abuse (T32 DA015040).
###end p 69
###begin article-title 70
###xml 48 53 <span type="species:ncbi:9606">human</span>
Structure and organization of the gene encoding human dopamine transporter
###end article-title 70
###begin article-title 71
###xml 76 81 <span type="species:ncbi:9606">human</span>
Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter
###end article-title 71
###begin article-title 72
###xml 2 7 <span type="species:ncbi:9606">human</span>
A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic TaqI RFLPs
###end article-title 72
###begin article-title 73
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR
###end article-title 73
###begin article-title 74
###xml 48 53 <span type="species:ncbi:9606">human</span>
Distribution of the 3' VNTR polymorphism in the human dopamine transporter gene in world populations
###end article-title 74
###begin article-title 75
###xml 32 37 <span type="species:ncbi:9606">human</span>
Population genetic study of the human dopamine transporter gene (DAT1)
###end article-title 75
###begin article-title 76
Global variation of a 40-bp VNTR in the 3'-untranslated region of the dopamine transporter gene (SLC6A3)
###end article-title 76
###begin article-title 77
Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA
###end article-title 77
###begin article-title 78
###xml 25 30 <span type="species:ncbi:10090">mouse</span>
###xml 92 97 <span type="species:ncbi:9606">human</span>
Molecular cloning of the mouse dopamine transporter and pharmacological comparison with the human homologue
###end article-title 78
###begin article-title 79
Single nucleotide polymorphisms distinguish multiple dopamine transporter alleles in primates: implications for association with attention deficit hyperactivity disorder and other neuropsychiatric disorders
###end article-title 79
###begin article-title 80
The 3' untranslated region of messenger RNA: A molecular 'hotspot' for pathology?
###end article-title 80
###begin article-title 81
VNTR (variable number of tandem repeat) sequences as transcriptional, translational, or functional regulators
###end article-title 81
###begin article-title 82
###xml 160 165 <span type="species:ncbi:9606">human</span>
Identification and characterization of the Hesr1/Hey1 as a candidate trans-acting factor on gene expression through the 3' non-coding polymorphic region of the human dopamine transporter (DAT1) gene
###end article-title 82
###begin article-title 83
Untranslated regions of mRNAs
###end article-title 83
###begin article-title 84
Association of attention-deficit disorder and the dopamine transporter gene
###end article-title 84
###begin article-title 85
###xml 153 161 <span type="species:ncbi:9606">children</span>
Mapping susceptibility loci in attention deficit hyperactivity disorder: preferential transmission of parental alleles at DAT1, DBH and DRD5 to affected children
###end article-title 85
###begin article-title 86
Haplotype study of three polymorphisms at the dopamine transporter locus confirm linkage to attention-deficit/hyperactivity disorder
###end article-title 86
###begin article-title 87
Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism
###end article-title 87
###begin article-title 88
###xml 105 113 <span type="species:ncbi:9606">children</span>
Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity
###end article-title 88
###begin article-title 89
The dopamine transporter gene is associated with attention deficit hyperactivity disorder in a Taiwanese sample
###end article-title 89
###begin article-title 90
###xml 29 34 <span type="species:ncbi:9606">human</span>
The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression
###end article-title 90
###begin article-title 91
Variation of variable number of tandem repeat sequences in the 3'-untranslated region of primate dopamine transporter genes that affects reporter gene expression
###end article-title 91
###begin article-title 92
The dopamine transporter gene (SLC6A3) variable number of tandem repeats domain enhances transcription in dopamine neurons
###end article-title 92
###begin article-title 93
###xml 76 81 <span type="species:ncbi:9606">human</span>
Promoter and intronic variants affect the transcriptional regulation of the human dopamine transporter gene
###end article-title 93
###begin article-title 94
Transient expression analysis of allelic variants of a VNTR in the dopamine transporter gene (DAT1)
###end article-title 94
###begin article-title 95
###xml 47 52 <span type="species:ncbi:9606">human</span>
Polymorphisms in the 3'-untranslated region of human and monkey dopamine transporter genes affect reporter gene expression
###end article-title 95
###begin article-title 96
###xml 163 169 <span type="species:ncbi:9606">humans</span>
The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans
###end article-title 96
###begin article-title 97
Prediction of dopamine transporter binding availability by genotype: a preliminary report
###end article-title 97
###begin article-title 98
###xml 65 70 <span type="species:ncbi:9606">human</span>
Genotype influences in vivo dopamine transporter availability in human striatum
###end article-title 98
###begin article-title 99
Increased Dopamine Transporter Availability Associated with the 9-Repeat Allele of the SLC6A3 Gene
###end article-title 99
###begin article-title 100
###xml 89 97 <span type="species:ncbi:9606">children</span>
Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD
###end article-title 100
###begin article-title 101
Association of the dopamine transporter gene (DAT1) with poor methylphenidate response [see comments]
###end article-title 101
###begin article-title 102
###xml 67 75 <span type="species:ncbi:9606">children</span>
Dopamine transporter genotype and methylphenidate dose response in children with ADHD
###end article-title 102
###begin article-title 103
###xml 110 118 <span type="species:ncbi:9606">children</span>
The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: relating to treatment response to methylphenidate
###end article-title 103
###begin article-title 104
Dopamine genes and ADHD
###end article-title 104
###begin article-title 105
Site-specific recombination: developments and applications
###end article-title 105
###begin article-title 106
Recombinase-mediated gene activation and site-specific integration in mammalian cells
###end article-title 106
###begin article-title 107
Limitation in use of heterologous reporter genes for gene promoter analysis. Silencer activity associated with the cloramphenicol acetyltransferase reporter gene
###end article-title 107
###begin article-title 108
Strategies for the use of site-specific recombinases in genome engineering
###end article-title 108
###begin article-title 109
Genome engineering using site-specific recombinases
###end article-title 109
###begin article-title 110
Flp-mediated integration of expression cassettes into FRT-tagged chromosomal loci in mammalian cells
###end article-title 110
###begin article-title 111
###xml 57 60 <span type="species:ncbi:10116">rat</span>
[3H]beta-CIT: a radioligand for dopamine transporters in rat brain tissue
###end article-title 111
###begin article-title 112
###xml 8 13 <span type="species:ncbi:9606">human</span>
Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT
###end article-title 112
###begin article-title 113
Frequency of long allele in serotonin transporter gene is increased in depressed suicide victims
###end article-title 113
###begin article-title 114
18F-labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporters
###end article-title 114
###begin article-title 115
###xml 51 56 <span type="species:ncbi:9606">human</span>
Membrane trafficking regulates the activity of the human dopamine transporter
###end article-title 115
###begin article-title 116
###xml 83 88 <span type="species:ncbi:9606">human</span>
Protein kinase-mediated bidirectional trafficking and functional regulation of the human dopamine transporter
###end article-title 116
###begin article-title 117
The dopamine transporter constitutively internalizes and recycles in a protein kinase C-regulated manner in stably transfected PC12 cell lines
###end article-title 117
###begin article-title 118
Contrast enhancement: a physiological effect of striatal dopamine?
###end article-title 118
###begin article-title 119
Dopamine gating of forebrain neural ensembles
###end article-title 119
###begin article-title 120
###xml 85 100 <span type="species:ncbi:10090">transgenic mice</span>
Flp recombinase promotes site-specific DNA recombination in embryonic stem cells and transgenic mice
###end article-title 120

